CoraLite®594-conjugated RALYL Monoclonal antibody
RALYL Monoclonal Antibody for IF/ICC, FC (Intra)
Host / Isotype
Mouse / IgG1
Reactivity
human, mouse, rat, pig
Applications
IF/ICC, FC (Intra)
Conjugate
CoraLite®594 Fluorescent Dye
CloneNo.
1F3F4
Cat no : CL594-67534
Synonyms
Validation Data Gallery
Tested Applications
| Positive IF/ICC detected in | HepG2 cells |
| Positive FC (Intra) detected in | HepG2 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| Flow Cytometry (FC) (INTRA) | FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
CL594-67534 targets RALYL in IF/ICC, FC (Intra) applications and shows reactivity with human, mouse, rat, pig samples.
| Tested Reactivity | human, mouse, rat, pig |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen | RALYL fusion protein Ag11676 相同性解析による交差性が予測される生物種 |
| Full Name | RALY RNA binding protein-like |
| Calculated molecular weight | 291 aa, 32 kDa |
| Observed molecular weight | 35-40 kDa |
| GenBank accession number | BC031090 |
| Gene symbol | RALYL |
| Gene ID (NCBI) | 138046 |
| RRID | AB_2920153 |
| Conjugate | CoraLite®594 Fluorescent Dye |
| Excitation/Emission maxima wavelengths | 588 nm / 604 nm |
| Form | Liquid |
| Purification Method | Protein G purification |
| Storage Buffer | PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3. |
| Storage Conditions | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
RALY RNA binding protein-like (RALYL) belongs to the RALY subfamily. RALYL locates in 8q21.2, the function of which is RNA-binding and nucleotide binding. The RALYL high expression in the normal adrenal, kidney and brain (Shyamsundar et al., 2005). Furthermore, RALYL expression down-regulated correlates with mental disorder (Lee et al., 2007), Parkinson's disease (Moran et al., 2006), brain cancer (Maris et al., 2008), adrenal cancer (Giordano et al., 2009) and kidney cancer (Higgins et al., 2003). The expression of RALYL was significantly low in Clear Cell Renal Cell Carcinoma and correlated with a poor prognosis in a large number of clinical samples. Our findings showed that RALYL may be a potential therapeutic target as well as a poor prognostic
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for CL594 RALYL antibody CL594-67534 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
